A West Virginia man whose wife may have died because of the dialysis medication she received has filed a GranuFlo lawsuit against its manufacturer, who also owns thousands of treatment centers in the U.S.

According to a complaint filed April 30 in Wyoming Circuit Court, the woman received hemodialysis at Fresenius Medical Care Charleston in June 2009 and suffered cardiac arrest immediately after. Her husband says the couple was inadequately warned about side effects that may stem from GranuFlo and NaturaLyte, two acid concentrates that were subject to a U.S. Food and Drug Administration (FDA) recall three years later.

Not only that, Fresenius “willfully misrepresented the high bicarbonate levels in their product produced and the increased buffer levels associated with its use in public information,” the suit alleges. GranuFlo lawyers for the plaintiff go on to accuse the company of ignoring safety information related to its products long before his wife received her treatment, putting she and possibly thousands of patients in danger of suffering life-threatening cardiovascular side effects. According to claims, the patient’s now-widower says Fresenius Medical Care’s negligence and fraudulent misrepresentation of GranuFlo and NaturaLyte cost him a long and happy relationship with his wife.

1,700 GranuFlo Recall Lawsuits Now Filed in Massachusetts Litigation

This Fresenius lawsuit is one of hundreds now filed in the U.S., many of which are now pending in a multidistrict litigation underway in the U.S. District Court, District of Massachusetts. A Case List updated on May 15th indicates that 1,717 federal GranuFlo and NaturaLyte-related claims are now filed in the jurisdiction after being brought by plaintiffs who allege similar injuries caused by the medications.

All of these lawsuits follow an FDA action in June 2012 that warned the general public about the dialysis drugs’ alleged association with strokes, heart attacks, sudden cardiac death and other serious heart problems. The company’s Urgent Product Notification two months earlier was insufficient in warning patients about these risks, plaintiffs allege, and was issued long after Fresenius first became aware of GranuFlo and NaturaLyte’s potential harm to patients. Among other things, a notice on March 29, 2012 alerted patients that the medications had a higher amount of an ingredient the body converts to bicarbonate than rival products, which may result in metabolic alkalosis, a condition associated with heart side effects.

Contact an Attorney to Learn More about GranuFlo Lawsuits

Call our Firm today for a free and confidential evaluation of your GranuFlo lawsuit at (877) 779-1414.

Published May 21, 2014 by